Skip to main content

Table 1 Baseline characteristics of studies included in the final meta-analysis

From: Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis

First author Publication year Country Age Male (%) Sample size Chemotherapy regimen Disease status Tumor stage (I and II) Jadad score
NAC SA Total
Cunningham [21] 2006 UK 62.0 78.7 250 253 503 Cisplatin; fluorouracil Resectable Gastroesophageal Cancer 43.8% 5
Hartgrink [22] 2004 Netherland NG NG 27 29 56 Methotrexate; 5-fluorouracil; leucovorin Resectable GC 53.6% 4
Hashemzadeh [23] 2014 Iran 59.2 75.7 22 52 74 Docetaxel; cisplatin; 5-fluorouracil Locally advanced GC 28.0% 1
Lygidakis [24] 1999 Greece 61.0 47.4 19 19 38 Mitomycin C; 5-fluorouracil; leucovorin; farmorubicin Resectable GC 36.8% 2
Qu [25] 2010 China 56.0 61.5 39 39 78 Docetaxel Advanced GC 0.0% 3
Schuhmacher [10] 2010 Europe 57.0 69.4 72 72 144 Cisplatin; fluorouracil Locally Advanced Cancer of the Stomach and Cardia 0.0% 3
Sun [26] 2011 China NG NG 29 26 55 Docetaxel; dexamethasone; cimetidine; phenergan Borrmann Type IV GC NG 1
Wang [27] 2000 China 54.5 83.3 30 30 60 5-fluorouracil Gastric cardia cancer 18.3% 1
Ychou [9] 2011 France 63.0 84.0 113 111 224 Fluorouracil; cisplatin Resectable Gastroesophageal Adenocarcinoma 31.1% 3
Yonemura [7] 1993 Japan 60.5 74.5 26 29 55 Cisplatin; mitomycin C; etoposide;l-(2-tetrahydrofuryl)-5-fluorouracil; uracil High-Grade Advanced GC 16.4% 2
Zhang [28] 2012 China NG 60.0 38 42 80 Calcium folinate; oxaliplatin; 5-fluorouracil Advanced GC 0.0% 2
Kobayashi [29] 2000 Japan NG NG 91 80 171 5-fluorouracil Resectable GC NG 2
  1. NAC neoadjuvant chemotherapy, SA surgery alone, GC gastric cancer NG not given